Trials / Recruiting
RecruitingNCT06291207
A Study to Evaluate the Efficacy and Safety of AD-224
A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 252 (estimated)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-224
Detailed description
Condition or disease : Essential Hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-224A | PO, Once daily, 8weeks |
| DRUG | AD-224B | PO, Once daily, 8weeks |
| DRUG | AD-224C | PO, Once daily, 8weeks |
| DRUG | Placebo of AD-224A | PO, Once daily, 8weeks |
| DRUG | Placebo of AD-224B | PO, Once daily, 8weeks |
| DRUG | Placebo of AD-224C | PO, Once daily, 8weeks |
Timeline
- Start date
- 2024-04-15
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
- First posted
- 2024-03-04
- Last updated
- 2025-02-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06291207. Inclusion in this directory is not an endorsement.